---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-25-000028"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:29:34.250301+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Curis gains FDA & EMA support for accelerated approval of emavusertib in PCNSL

## Summary
- FDA and EMA agree TakeAim Lymphoma study may support accelerated approval path for PCNSL.
- Emavusertib granted Orphan Drug Designation for PCNSL in both US and EU.
- In 20 BTKi-experienced PCNSL patients: 6 objective responses, 4 complete responses.
- Q4 2024 net loss $9.6M ($1.25/share); FY2024 net loss $43.4M ($6.88/share).
- Cash $20.0M at Dec 31, 2024; plus $10M from March 2025 offerings funds ops into Q4 2025.

## SEC filing metadata
- accession: 0001108205-25-000028
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820525000028/0001108205-25-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820525000028/cris-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-25-000028
- JSON: https://secwatch.observer/filing/0001108205-25-000028.json
- Plain text: https://secwatch.observer/filing/0001108205-25-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.